The tissue distribution of the human b b 3 -adrenoceptor studied using a monoclonal antibody: Direct evidence of the b b 3 -adrenoceptor in human adipose tissue, atrium and skeletal muscle 2,3 The human b 3 -adrenoceptor was later cloned by Emorine et al. 4 The pharmacology of the cloned b 3 -adrenoceptor agreed with the pharmacological data previously obtained in rodent adipose tissue, gut, and skeletal muscle in that the badrenoceptors in these tissues were insensitive to classical b-adrenoceptor antagonists such as propranolol.
Introduction b-adrenoceptors were originally classi®ed into two subtypes, b 1 and b 2 , based on the relative potencies of the agonists isoproterenol, adrenaline and noradrenaline. 1 This classi®cation was veri®ed by the isolation of cDNAs encoding the b 1 -and b 2 -adrenoceptors. 2, 3 The human b 3 -adrenoceptor was later cloned by Emorine et al. 4 The pharmacology of the cloned b 3 -adrenoceptor agreed with the pharmacological data previously obtained in rodent adipose tissue, gut, and skeletal muscle in that the badrenoceptors in these tissues were insensitive to classical b-adrenoceptor antagonists such as propranolol. 5 ± 8 Aryloxypropanolamine b 1 ab 2 adrenoceptor antagonists, exempli®ed by CGP12177, evoke a lipolytic response in rat adipose tissue through agonism at b 3 -adrenoceptors. 9 Similarly, selective b 3 -adrenoceptor agonists, such as BRL-37344, showed similar or greater potency than isoproterenol in stimulating lipolysis, but were much less potent than isoproterenol in stimulating responses mediated by b 1 -or b 2 -adrenoceptors. 10 The assessment of the pharmacological role of b 3 -adrenoceptors in human tissues has proved more controversial. For example, lipolysis in human white adipocytes induced by isoproterenol is sensitive to propranolol. 11 Also, CGP12177-induced lipolytic responses have been demonstrated by some 12 ± 14 but not others. 9, 15 It is now evident from comparisons of cloned human and rat b 3 -adrenoceptors that there are signi®cant species differences in pharmacology. 16 Attempts to detect b 3 -mRNA in human tissues using reverse-transcription PCR have also given conicting results. Krief et al 17 detected b 3 -adrenoceptor mRNA in several tissues, including gall bladder, adipose tissue and colon, while Thomas and Liggett gall bladder, stomach, small intestine, adipose tissue and prostate gland. 19 In addition, b 3 -adrenoceptor mRNA has been reported in human brain, 20 although this was not detected by others. 19 These con¯icting results may, in part, be due to the relatively low levels of b 3 -adrenoceptor gene expression in human tissue. For example, Northern blotting analyses 21, 22 indicate that the b 3 -adrenoceptor mRNA level in human white adipose tissue is some 50-fold lower than that in rodent white fat.
Without a speci®c pharmacological or molecular probe for the b 3 -adrenoceptor, it has proved dif®cult to assess the functional signi®cance of this adrenoceptor subtype in man. Data describing the immunohistochemical localisation of the b 3 -adrenoceptor has been limited to a single study using an anti-peptide polyclonal antibody, 23 which detected the receptor only in human gall bladder, a tissue that exhibits a relatively high level of b 3 -adrenoceptor mRNA. 17, 19 The relative lack of sensitivity of this approach may be due to the dif®culty of producing a suitable high af®nity antibody using a short polypeptide immunogen.
In this paper we describe the development of a high af®nity monoclonal antibody, raised against the human b 3 -adrenoceptor expressed on a transfected mammalian cell line, and the immunohistochemical detection of the b 3 -adrenoceptor in several human tissues.
Methods

Cell lines
The human b 3 -adrenoceptor gene was obtained under licence from Dr S B Liggett (Duke University Medical Center, Durham, NC), subcloned and transfected into CHO (Chinese Hamster Ovary) dhfr 7 cells as previously described; 24 four subclones expressing different levels of the human b 3 -adrenoceptor were studied, designated C38, C15, D57 and D43 expressing b 3 -adrenoceptors at 130, 400, 1300 and 3000 fmolamg respectively. CHO cells expressing human b 1 -(7000 fmolamg) and b 2 -(2300 fmolamg) adrenoceptors were obtained under licence from A D Strosberg (Universite Paris VII, Institut Cochin de Genetique Moleculaire, Paris) and those expressing the rat b 3 -adrenoceptor (770 fmolamg) from J C Venter (NIH, Bethesda). 25 Cells were cultured in a-MEM (Modi®ed Eagle Medium) growth medium (Life Technologies, Paisley) containing 10% vav dialysed foetal calf serum. Medium for the CHO b 3 D57 and D43 clones was supplemented with 100 nM methotrexate and 2 mM glutamine. Receptor density values were determined by saturation binding of [ 125 I]-iodocyanopindolol. 24 Immunisation and hybridoma production CBHaCbi rats (National Institute for Medical Research, UK, Mill Hill) were immunised on four occasions with 2Â10 7 CHO b 3 .D43 cells, at 21 ± 28 d intervals intraperitoneally. Three days after the ®nal immunisation, mesenteric lymph node cells were removed and frozen. After storage in liquid nitrogen for 7 d these cells were thawed and fused with rat myeloma Y3-Ag 1.2.3 cells. 26 Hybridomas were cultured in a 1 : 1 mixture of DMEM (Dulbecco's Modi®ed Eagle Medium) and Ham's F12 (Life Technologies, Paisley) supplemented with 10% vav FBS (foetal bovine serum) (Hyclone Europe Ltd, Cramlington), cloned by the limiting dilution method and monoclonal antibody puri®ed by Protein G af®nity chromatography (Bioprocessing Ltd., UK). Isotype was determined using a commercial kit (Serotec Ltd., Oxford).
Hybridoma screening assay CHO b 3 .D43 or parental CHO non-transfected cells were grown to con¯uency and then washed with 5% FBSaDMEM. Hybridoma samples were added to plates seeded with parental CHO cells for 30 min at room temperature to pre-adsorb anti-CHO binding and then the pre-adsorbed supernatant samples were transferred to fresh CHO b 3 .D43 or parental cell-coated plates and incubated for 30 min at room temperature. The wells were washed and 125 I-sheep anti-rat IgG Fab (prepared in-house, 2Â10
5 CPM per well in 50 ml of 5% FBSaDMEM) was added and the plates incubated for a further 30 min at room temperature. The plates were washed again and the cells lysed by addition of 1% sarcosyl in 0.5 M NaOH (200 mlawell). After 10 min at room temperature the contents of each well were counted (Innotron Hydragamma 16) and the results expressed as the ratio of counts bound to the CHO b 3 .D43 cell line compared with the binding to parental non-transfected CHO cells.
Receptor solubilisation, deglycosylation and Western blotting CHO cell pellets, prepared from 1Â10 8 cells, were resuspended in 2 ml ice-cold TE buffer (10 mM Tris, 1 mM EDTA.Na 2 , pH 7.4) in the presence of protease inhibitors (1 mgaml aprotinin, 200 mM AEBSF (4-(2-aminoethyl) benzene sulphonyl¯uoride), 10 mM Leupeptin, 1 mM Pepstatin A). Cells were then homogenised in a Potter homogeniser tube (620 rpmÂ10 strokes) and the cell membrane fraction sedimented by centrifugation (88,000 gÂ20 min at 4 C). The pellet was resuspended in 1 ml TEC (TE containing 0.3% wav sodium deoxycholate) or TEDC (TE containing 0.3% wav sodium deoxycholate and 1% wav digitonin) buffer and then left to stand on ice for 45 min with occasional mixing. Solubilised b-adrenoceptor was collected as the supernatant following centrifugation as before. Aliquots were stored at 7 40 C. For removal of N-linked complex and high mannose type carbohydrate, solubilised receptor in TEC buffer was mixed with an equal volume of a mixture of Endoglycosidase F and Peptide-N-Glyco- Detergent-solubilised CHO cell membrane fractions prepared as described above were separated by SDS-PAGE on 10 ± 15% polyacrylamide gradient gels using the Pharmacia Phastsystem. Following electrophoretic separation, the proteins were then transferred onto PVDF membrane using the PhastSystem semidry western blotting module (1 mAacm 2 for 15 min, in 48 mM Tris, pH 9.2, 39 mM Glycine, 20% vav methanol). The membranes were then blocked by overnight incubation in 0.45% vav ®sh gelatin (Biocell), 0.01 M NaH 2 PO 4 , pH 7.4, 0.15 M NaCl, 0.02% wav polyvinylpyrrolidone-40, 0.02% wav Ficoll 400. Primary antibody (hybridoma supernatant or puri®ed monoclonal antibody) was diluted in reagent buffer (0.5% wav BSA, 0.25% wav bovine g-globulin, 50 mM Tris, pH 7.4, 0.15 M NaCl, 1 mM MgCl 2 ) and incubated for 1 h at room temperature with shaking. Bound antibody was detected by incubation with goat anti-rat IgG-biotin (Vector, 1a2000) followed by streptavidin-biotinylated HRP complex (Amersham, 1a2000) in reagent buffer, followed by enhanced chemiluminescence (Amersham). The membranes were washed 3 ± 5 times between each incubation step in 10 mM Tris, pH 7.4, 0.15 M NaCl, 0.05% vav Tween-20.
Flow cytometry
Assessment of Mab binding speci®city and kinetics All cells were harvested from an actively growing suspension culture immediately prior to each analysis. Puri®ed monoclonal antibody was incubated with aliquots of cell suspensions containing 3 ± 5Â10 6 cells for 30 min at room temperature on an endover-end mixer. Cells were sedimented (300 gÂ5 min) and resuspended in 2 ml buffer (0.05 M Na 2 HPO 4 , 0.15 M NaCl, 5 mM EDTA, 0.5% wav BSA (bovine serum albumin), pH 7.4). The washing step was repeated and the cells were resuspended in 2 ml of buffer containing goat anti-rat IgGuorescein (Vector Laboratories, Ltd, Peterborough, 1a500 dilution) followed by a further incubation for 30 min at room temperature. After two ®nal washing steps with buffer the bound¯uorescence was measured in a Facstar ¯ow cytometer (Becton Dickinson, Oxford). Fluorescence data was collected using a four decade logarithmic ampli®er. To calculate the mean¯uorescence of each sample the data was gated to exclude dead cells and the¯uorescence values converted to equivalent linear values prior to calculation of the mean¯uorescence.
To determine the kinetics of antibody binding directly labelled (via¯uorescein isothiocyanate) puri®ed monoclonal antibody (designated Mab 72C) and its Fab fragment was used. A modi®ed input system was constructed that allowed unlabelled cells to be analysed. At time 0, an aliquot of the directly labelled probe was injected into the cell suspension without disturbing the¯ow characteristics. Data was collected at discrete time intervals for several minutes. The mean¯uorescence of the cells was then calculated and plotted as a function of the mid time of the data ®le. In all cases the¯uorescence reached a plateau value after 4 min.
Quantitative studies For measurement of receptor density and assessment of the time course of antibody binding, cells were incubated with a Fab fragment of Mab 72c that had been conjugated to¯uorescein via an ± SH group. This allowed accurate quantitation of the Fab-¯uorescein concentration, since the maximal uorescein : protein will equal 1.0 (only 1 ± SH per mole of Fab available). Under saturating binding conditions (10 mg Fab-¯uoresceinaml cell suspension containing 5Â10 6 cells incubated for 30 min at room temperature) it was possible to correct for the effect of unconjugated Fab (27% of total) on the¯uorescein binding response. To correct for non-speci®c binding, the same conditions were used with CHO b 1 cells and the¯uorescence signal subtracted from that measured for CHO b 3 binding.
Immunohistochemistry
For light microscopy, aliquots of 5Â10 6 cells from clones D43, D57, C15, C38, CHO-b 1 and CHO-b 2 were sedimented (300 gÂ5 min) and resuspended in 10% vav neutral buffered formalin for at least 1 h. In order to facilitate ease of handling, ®xed cells were resuspended in 3% wav agarose (Type IX, Sigma, Poole) in 1.5 ml Eppendorf tubes maintained at 37 C, re-sedimented and allowed to cool to 4 C. The solidi®ed cell pellets were then removed and cut into pieces for processing to wax and 5 mm sections. Human tissue samples were provided by the Department of Histopathology, St George's Hospital, London (with local Ethical Committee approval). All samples were ®xed in 10% vav neutral buffered formalin and processed in a similar manner as the CHO cell agarose pellets.
Light microscopy labelling studies were carried out using Mab 72c at 0.2 mgaml and detection with antirat IgG Elite ABC (Avidin biotin peroxidase complex) kit (Vector Laboratories, Ltd, Peterborough) and DAB (Diaminobenzidine). For indirect immunogold labelling, Mab 72c (2.36 mgaml) was detected with a goat anti-rat 1 nm gold conjugate (British Biocell International, Cardiff) 1a100 in PBS (phosphate buffered saline) intensi®ed with silver (British Biocell International, Cardiff) and examined using epi-polarized light. For electron microscopy, cells from clones D43, C15, C38 and CHO-b 1 were ®xed in 2% paraformaldehyde, 0.05% glutaraldehyde in PBS for 1 h, pelleted in agarose and dehydrated using a progressive Tissue distribution of the human-b 3 -adrenoceptor PD Chamberlain et al lowering temperature method, 27 in a Reichert AFS freeze-substitution unit (Leica, Milton Keynes). Cells were then embedded in Lowicryl HM20 resin followed by UV polymerization at 7 45 C for 48 h. Sections (50 nm) were cut and indirectly labelled using Mab 72c (0.78 ± 2.36 mgaml in Tris buffered saline, overnight at 4 C) followed by a 1 h secondary incubation with goat anti-rat 10 nm gold antibody (1a20 in PBS) and uranyl acetatealead citrate staining. The same negative controls used for¯ow cytometry were employed for light and Electron microscopy studies.
Time resolved¯uorescence detection of b 3 -adrenoceptor labelling in human white adipose tissue Adipose tissue was obtained from female patients undergoing surgery for the treatment of breast cancer at St George's Hospital (University of London, London) after approval of the hospitals ethics committee. Adipocytes were prepared using a modi®cation of the method of Rodbell 28 employing collagenase digestion (272 Uaml collagenase in Krebs buffer) for 30 ± 45 min.
A membrane-bottomed plate (Millipore Ltd, Watford) was pre-wetted with 100 mlawell 10 mM HEPES (N-2-Hydroxyethylpiperazine-2-ethanesulfonic acid), pH 7.4. The fresh adipocyte suspension (100 mlawell) was then added and washed with ice-cold 10 mM HEPES, pH 7.4; non-speci®c binding sites werè blocked' by addition of 250 mlawell 1% wav BSA in Tris buffered saline and incubated for 45 min at room temperature. Wells were then washed twice and 100 ml biotinylated Mab (72c or anti-IL5 5D3), diluted in Europium assay buffer (Wallac, Milton Keynes) containing 100 mgaml rat IgG was added to each well and incubated for 30 min at room temperature. Wells were washed (four times) and 100 ml streptavidineuropium (200 ngaml, Wallac) in europium assay buffer was added and incubated for 15 min at room temperature followed by 6 washes prior to the addition of 100 ml enhancer per well. After shaking for 2 min, 90 ml per well was transferred into Del®a plates, and the time-resolved¯uorescence signal was measured using the Del®a system as described. 29 
Results
Monoclonal antibody development
Cell fusions were completed using splenocytes from two rats immunised with CHO b 3 .D43 cells. 17 hybridomas were generated that gave CHO b 3 .D43anon-transfected CHO binding ratios in the range 4.0 ± 13.7. Primary clones were isolated from six of these hybridomas and those giving binding ratios greater than 5.0 at 1a100 dilution of hybridoma supernatant were further examined by SDSPAGEaWestern blotting. One hybridoma, 72c, was taken through a second round of cloning and then scaled up to a 1 l (litre) suspension culture for Mab production. Puri®ed rat IgG2ak was isolated by Protein G af®nity chromatography. Using indirect labelling (Mab 72c at 1 mgaml followed by anti-rat IgG-¯uorescein) a very substantial increase in¯uorescence was obtained for the highestexpressing b 3 clone (D43), such that the mean signal was some 20-fold over background (Table 1) . This signal reduced with decreasing human b 3 -adrenoceptor density, to the extent that the signal obtained for the lowest expressing clone, C38 (130 fmolamg), was similar to that measured for the D43 clone in the absence of Mab 72c or with an unrelated primary Mab 5D3. 
Evaluation of Mab72c using cloned b-adrenoceptors
Western blotting of human b 3 -adrenoceptors from clone D43 using Mab72c revealed a diffuse band in the 60 ± 70 kDa region. This band was absent from the lanes containing human b 1 -or b 2 -adrenoceptors. An equivalent amount of cell membranes expressing comparable b-adrenoceptor densities were used (Figure 1a). The magnitude of the b 3 signal was reduced with decreasing receptor density (D43 b C15 b C38, Figure 1b). A band-shift occurred following treatment with deglycosylation enzymes to a region of apparent molecular weight 40 kDa which agrees with the value predicted (43 kDa) from the amino acid sequence of the b 3 -adrenoceptor (Figure 1c). The band detected at approximately 100 kDa may represent aggregated receptor. The b 3 -speci®c band was also detected following immunoprecipitation with Mab 72c-Sepharose. This band was not detected for receptor solubilised from CHO cells expressing the rat b 3 adrenoceptor (data not shown).
Transmission electron microscopy Ð CHO cells
Post-®xation labelling was found to be of a generally low level with isolated clusters of gold labelling occurring. Labelling was localized on the cell membrane ( Figure 2e ) and was often seen associated with cytoplasmic processes (Figure 2f ).
Light microscopy Ð human tissues Positive labelling was detected in a small sub-population of smooth muscle cells of the lamina propria of the gall bladder in one out of three tissue samples (Figure 3a) . A similar pattern was also consistently observed in colon (three samples, including one of the longitudinal muscles of the taenia coli), prostate, right atrium (in three out of four samples) and gastrocnemius muscle (in two out of three samples; Figure 3b ± f). No labelling was detected in lung, left ventricle, appendix, uterus or thyroid. Examination of eleven samples of adipose tissue from breast, peri-renal and axillary sites proved inconclusive due to problems of interpreting labelling of the thin walled adipocytes.
Time resolved¯uorescence Ð adipocyte membranes To overcome the problem of lack of surface area in the cell wall for labelling by Mab72c in the light microscopy studies, adipocyte membranes were prepared, making a greater surface area available for antibody quanti®cation. In these studies a statistically signi®cant speci®c labelling of adipocyte membrane preparations was detected at antibody concentrations similar to those used for light microscopy ( Figure 4) . 
Assessment of peptide reactivity
No binding of Mab 72c to either a series of hexameric peptides spanning amino acids 1 ± 28 of the b 3 adrenoceptor (SPOTs kit, Cambridge Research Biochemicals) or the 17 ± 28 peptide in an ELISA was detected (data not shown).
Discussion
In rodents, b 3 -adrenoceptors play a signi®cant role in the control of body weight and glucose homeostasis. 10 A similar role has been hypothesised in man such that selective activation of this receptor would lead to therapeutic bene®t in obese patients and in Type 2 diabetes. 30 This possibility is supported by the ®nding in a number of studies of an increased tendency to weight gain and accelerated onset of non-insulin dependent diabetes mellitus in individuals carrying an allelic variant (Trp 64Arg) of the b 3 -adrenoceptor. 31 However, contrasting results have also been obtained. 32 Despite substantial effort, it has proved dif®cult to unequivocally demonstrate expression of mRNA for this receptor sub-type in the relevant human tissues. 17 ± 22 Furthermore, the only EST hybridising to the human b 3 -adrenoceptor so far identi®ed (Gen Bank: HSBAREIX 70811, A1276134) was obtained from a library derived from a pool of three organs: foetal heart, melanocyte and uterus (personal communication, Klaus Duecker and Chris Southan, SB Pharmaceuticals).
The major evidence that the b 3 -adrenoceptor is expressed in human tissues comes from functional studies using the b 1 ab 2 adrenoceptor antagonist CGP 12177, which has partial agonist activity at the human b 3 -adrenoceptor expressed in CHO cells. 33 In human tissues responses to CGP 12177 are not blocked by standard b 1 -or b 2 -adrenoceptor antagonists. Thus both human circular and taenia coli preparations are relaxed by CGP 12177. 34 ± 36 Similarly in human white Tissue distribution of the human-b 3 -adrenoceptor PD Chamberlain et al adipocytes, CGP 12177 has been demonstrated to have a lipolytic action in most 12 ± 14 but not all studies, 9 ± 5 that is poorly blocked by the standard b 1 -and b 2 -adrenoceptor antagonists. Interpretation of studies on CGP 12177 is complicated by its mixed actions. In addition to its b 1 -or b 2 -antagonism, it is claimed to be an activator of the putative b 4 -adrenoceptor. Thus, CGP 12177 has an inotropic response on human right atrial appendage that is not mediated by the b 3 -adrenoceptor. 37, 38 All of these studies have emphasised the need to be able to detect the b 3 -adrenoceptor protein in human tissues. After initial attempts to develop b 3 -adrenoceptor speci®c antibodies against synthetic peptide immunogens had been unsuccessful, we chose to develop monoclonal antibodies from rats immunised with whole CHO cells expressing the human b 3 -adrenoceptor at high density. Both the reactive band identi®ed with one antibody, Mab 72c, in the 60 ± 70 kDa region on Western blots of solubilised human b 3 -adrenoceptor and the band-shift to approximately 43 kDa following deglycosylation, were consistent with observations made for other b-adrenoceptor subtypes. 39 ± 41 The diffuse nature of the Mab 72c-reactive band most probably re¯ects heterogeneity of the N-linked complex and high-mannose type carbohydrate chains located close to the N-terminus of the receptor. The titration of this signal with the receptor density in a panel of CHO b 3 -adrenoceptor cell lines provided good evidence for speci®city.
The identity of the epitope recognised by Mab 72c has not been established. However, as cells examined in the¯ow cytometer were non-permeabilised, Mab 72c must recognise an epitope on an extracellular domain of the human b 3 -adrenoceptor. Stability of recognition to formaldehyde ®xation or to reduction of solubilised receptor in the presence of SDS suggested a linear rather than a conformational epitope. Given the lack of reactivity with the rat b 3 -adrenoceptor, it seemed most likely that the epitope was located in the ®rst extracellular domain (amino acids 1 ± 35) where there is greatest divergence of the sequence of one of the human extracellular domains from that of the rat. However, we failed to detect Mab 72c binding to a series of hexameric peptides spanning residues 1 ± 28, or to a synthetic peptide comprising residues 17 ± 28. Furthermore, the Mab reacted strongly with both the glycosylated and deglycosylated forms of the solubilised receptor on SDSPAGEaWestern blotting, indicating that the complex carbohydrate associated with the ®rst extracellular domain did not in¯uence recognition of the receptor by Mab 72c. The absence of an effect of the Mab on the binding of [ Fluorescence labelling analysed by¯ow cytometry was similar for both fresh and ®xed cells, proving that the b 3 -adrenoceptor withstands formalin ®xation. Hence ®xed, rather than fresh, human tissue could be considered for immunolocalisation studies. Microscopy showed clear evidence of surface labelling of the CHO cells, particularly in immunogold labelled preparations (light and electron microscopy), which appeared similar to that described for b 2 -adrenoceptors in 293 cells, 42 with the presence of clusters of b 3 -adrenoceptors located at the cell surface. These receptors were detected also by immunohistochemistry in gall bladder, colon and prostate, con®rming previous mRNA studies. 17, 19 In these sites, receptors were localised on a sub-population of cells, a fact not detected by whole tissue mRNA analysis. Possibly, this re¯ects clustering of b 3 -adrenoceptors in sympathetically innervated cells. Furthermore, it is noteworthy that the staining pattern obtained in gall bladder was quite different from that reported in a previous study 23 using a polyclonal anti-peptide antibody. In the latter report, staining was associated primarily with arteriolar vascular smooth muscle cells, with negligible staining in the lamina propria. Unfortunately, these authors did not report data from other human tissues for comparison. The detection of Mab 72c binding in longitudinal smooth muscle of the colon agrees with the localisation of atypical (non-b 1 - 43 and supports a role for the b 3 -adrenoceptor in mediating relaxation responses. 34 ± 36 Initial studies on human adipose tissue using immunohistochemistry were inconclusive. To detect a b 3 -adrenoceptor signal and therefore con®rm the ability of Mab72c to detect b 3 -adrenoceptors in adipose tissue, adipocyte membranes were separated and concentrated. This effectively increased the surface area of detection and thereby overcame the inherent inef®-ciency of the whole tissue studies. Using this approach and time-resolved¯uorescence, a signi®cant b 3 -adrenoceptor signal was obtained using similar antibody concentrations to those used in the tissue distribution studies. The fact that only a low signal was detected may re¯ect a low receptor density, as levels of b 3 -adrenoceptor mRNA appear lower in subcutaneous than in visceral fat depots, 17 or possibly a difference in expression between subpopulations of adipocytes.
Our observation that Mab 72c produced no labelling in the lung gave added con®dence to the b 3 selectivity (over b 2 ) for the human tissue studies. This was particularly important in substantiating our detection of b 3 adrenoceptors in right atrium and skeletal muscle. In the case of right atrium, Berkowitz et al 19 speculated that the weak and variable mRNA signal seen in their samples may have originated in attached fat. The same conclusion was reached by Evans et al 44 for heart and skeletal muscle. The present study demonstrates that the location is, in fact, in the myocardial cells and represents the ®rst immunohistochemical localization of b 3 -adrenoceptors in the human heart. However, at least some selective agonists at the human b 3 -adrenoceptor appear unable to enhance the contractility of human right atrial appendage 45 and it seems probable that much of the effect of CGP 12177 is mediated by the putative b 4 -adrenoceptor. Since this latter receptor has not been cloned yet, we cannot rule out the possibility that Mab 72c detects the b 4 -adrenoceptor also.
In contrast to human atrium we were unable to detect b 3 -adrenoceptors in human ventricle, which was surprising in light of the pharmacological evidence described by Gauthier et al, 46 especially as these workers described an order of potency by selective b 3 -adrenoceptor agonists in which CGP 12177 was least ef®cacious, indicating that the effects were unlikely to be mediated via the putative b 4 -adrenoceptors. 38 In addition to the b 3 -adrenoceptor signal in the atrium a signi®cant signal was obtained in skeletal muscle using Mab 72c. This ®nding contrasts with the more tenuous evidence for b 3 -adrenoceptor mRNA expression in human skeletal muscle. 19, 44 Experiments in rodents have indicated the presence of an atypical badrenoceptor in skeletal muscle, although this receptor does not have identical characteristics to the b 3 -adrenoceptor. 47, 48 The present studies suggest that either the b 3 -adrenoceptor or an atypical b-adrenoceptor that cross-reacts with Mab 72c is present in human skeletal muscle.
In summary, Mab 72c is an important addition to the armentarium of reagents that are available to unravel the complexities of b 3 -adrenoceptor function in man.
